Abstract: The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.

Abstract: The present invention relates to a method for detecting cardiovascular oxidative stress in an individual, comprising detecting in a blood sample from the individual modification of a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homolog or variant thereof. The invention further relates to a kit for detecting cardiovascular oxidative stress in an individual, the kit comprising at least one agent for detecting the presence of a modification in a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homolog or variant thereof, wherein said modification is a result of oxidation.

Abstract: The present invention relates to a method for detecting cardiovascular oxidative stress in an individual, comprising detecting in a blood sample from the individual modification of a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homologue or variant thereof. The invention further relates to a kit for detecting cardiovascular oxidative stress in an individual, the kit comprising at least one agent for detecting the presence of a modification in a cysteine at position 45 of the ?1-subunit of the human erythrocyte ATP-dependent Na+K+ pump protein or of an equivalent cysteine in a homologue or variant thereof, wherein said modification is a result of oxidation.

Abstract: The present disclosure relates generally to the field of cancer diagnosis. More specifically, the present disclosure relates to the identification and use of monoubiquitination of histone 2B as a biomarker for the diagnosis and prognosis of cancer including, but not limited to, parathyroid cancer. The present disclosure also relates to the identification of binding between CDC73 and RNF20, and the use of CDC73 and RNF20 in an assay for screening for an agent that modulates monoubiquitination of a histone protein.